Results 11 to 20 of about 365,681 (229)

Oral ethinylestradiol in castration resistent prostate cancer: 10 year experience [PDF]

, 2015
To describe our 10-year experience with the use of oral ethinylestradiol in the treatment of metastatic castration-resistant prostate cancer. METHODS: From February 2000 to April 2010, 116 patients with a metastatic castration-resistant prostate cancer
Aggarwal, Beer, Bonkhoff, Bono, Chadha, Corey, Di Silverio, Gasent Blesa, Izumi, Kitahara, Limonta, Montgomery, Shamash, Stein, Takezawa, Tannock, Wilkins   +16 more
core   +1 more source

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS

Jurnal Urologi Indonesia, 2016
Objective: In Hasan Sadikin General Hospital Bandung prostate biopsy is recommended for patients with prostate specific antigen (PSA) levels above 10 ng/mL or PSA density (PSAD) above 0.15 if PSA in between 4–10 ng/mL.
Daniel Simanjuntak, Ferry Safriadi
doaj   +1 more source

Components of cell-matrix linkage as potential new markers for prostate cancer [PDF]

, 2011
Prostate cancer is one of the most common tumor diseases worldwide. Often being non-aggressive, prostate tumors in these cases do not need immediate treatment.
Eble, Johannes Andreas, Navdaev, Alexey
core   +2 more sources

Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA) [PDF]

, 2013
The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation with a 15-mer phage
A Ghosh, AC Pawlyk, AM Quinn, CW Diehnelt, D Hessels, D Shen, DB Sodee, Duanwen Shen, E Basch, F Yi, Fei Xie, GA Lazar, H Liu, H Liu, H-S Lim, HD Agnew, IM Thompson, Irina U. Agoulnik, J Yu, JA Arter, JR Mesters, JR Newton, KA Noren, MI Davis, MI Milowsky, MJ Morris, MJ Morris, MJ Roobol, NH Bander, RK Nam, S Aggarwal, S Kim, S Minner, SE Lupold, SM Hillier, SR Banerjee, SR Banerjee, SR Banerjee, SR Banerjee, SS Chang, SZ Li, TJ Wigle, V Humblet, W. Barry Edwards, Y Chen, Y Chen, Y Chen, Z Xiao, ZY Zhu   +48 more
core   +12 more sources

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer

Prostate International, 2013
Racial differences exist in the incidence of prostate cancer (PCa). Although many studies have looked at the performance of prostate-specific antigen (PSA) and PSA density (PSAD) in the detection of PCa, only a few have looked at it in relation to ...
Ahmad Anies Shahab, Doddy M. Soebadi, Wahjoe Djatisoesanto, Sunaryo Hardjowijoto, Soetojo Soetojo, Lukman Hakim   +5 more
doaj   +1 more source

Accuracy of elastic fusion biopsy in daily practice: results of a multicenter study of 2115 patients [PDF]

, 2018
OBJECTIVES: To assess the accuracy of Koelis fusion biopsy for the detection of prostate cancer and clinically significant prostate cancer in the everyday practice.
Albisinni S, Altobelli E, Baco E, Beatrici V, Cantiani A, Carbone A, Ciccariello M, Descotes JL, Dubreuil-Chambardel M, Eldred-Evans D, Fasolis G, Ferriero M, Fiard G, Forte V, Giacobbe A, Gontero P., Kumar P, Lacetera V, Marra G, Mozer P, Muto G, Oderda M, Papalia R, Pastore A, Peltier A, Piechaud T, Roche JB, Roupret M, Rouviere O, Simone G, Van Velthoven R   +30 more
core   +1 more source

Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: A nested case-control study [PDF]

, 2014
Vitamin D pathway single nucleotide polymorphisms (SNPs) are potentially useful proxies for investigating whether circulating vitamin D metabolites [total 25-hydroxyvitamin-D, 25(OH)D; 1,25-dihydroxyvitamin, 1,25(OH)2D] are causally related to prostate ...
Bonilla, Carolina, Donovan, Jenny L., Evans, David M., Fraser, William D., Gilbert, Rebecca, Hamdy, Freddie C., Kemp, John P., Lane, J. Athene, Lathrop, Mark, Lewis, Sarah, Martin, Richard M., Metcalfe, Chris, Neal, David E., Smith, George Davey   +13 more
core   +4 more sources

All care, but whose responsibility? Community juries reason about expert and patient responsibilities in prostate-specific antigen screening for prostate cancer [PDF]

, 2016
General practitioners have implicitly been given responsibility for guiding men’s decisions about prostate-specific antigen–based screening for prostate cancer, but patients’ expectations of the bounds of this responsibility remain unclear.
Carter, S, Degeling, C, Rychetnik, L
core   +3 more sources

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia

Asian Journal of Andrology, 2015
In Western countries, clinical trials on prostate cancer screening demonstrated a limited benefit for patient survival. In the Asia-Pacific region, including Japan, the rate of prostate-specific antigen (PSA) testing remains very low compared with ...
Yasuhide Kitagawa, Mikio Namiki
doaj   +1 more source

A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy – The PROPER 1 trial

Clinical and Translational Radiation Oncology, 2022
Background and purpose: The treatment of biochemical recurrence (BCR) after prostatectomy is challenging as the site of the recurrence is often undetectable.
Adalsteinn Gunnlaugsson, Vilberg Johannesson, Elinore Wieslander, Eva Brun, Ulrika Bitzén, Olof Ståhl, Ola Bratt, Göran Ahlgren, Tomas Ohlsson, Elisabeth Kjellén, Per Nilsson   +10 more
doaj   +1 more source